Allergan Re-submits Application
Following discussions with the Scottish Medicines Consortium (SMC), Allergan will re-submit an application for OZURDEX for adult patients with macular oedema due to retinal vein occlusion (RVO) in early 2012. A company spokesman said that while Allergan was surprised and disappointed to learn of the SMC’s decision not to recommend OZURDEX for use in the National Health Service in Scotland, the company is committed to bringing the medication to Scottish patients with either form of RVO; central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
“This is particularly important for Scottish patients with BRVO who do not currently have a reimbursed pharmacological treatment option,†he said.
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Picture This: Photo Contest Winners
ESCRS 2025 Refractive and Cataract Photo Contest winners.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.